Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2011-06-15FDA Approved: RISPERIDONE — Supplemental Application (Janssen Pharmaceutical, Inc.)
The FDA approved Janssen Pharmaceutical, Inc.'s supplemental application for risperidone, resulting in updated labeling.
-
FDA approval · 2011-06-15FDA Approved: RISPERDAL M-TAB — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for Risperdal M-TAB (risperidone) filed by Janssen Pharmaceuticals, Inc., resulting in an updated/ex…
-
CLINICAL_TRIALS trial_result · 2011-06-13Clinical Trial Update: A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal Function [Phase 1]
This Phase 1 pharmacokinetic study evaluates ER OROS Paliperidone in volunteers with normal and impaired renal function to understand the im…
-
CLINICAL_TRIALS trial_result · 2011-06-10Clinical Trial Update: A Study of Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS Paliperidone [Phase 1]
Phase 1 study assessing dopamine D2 receptor occupancy after a single oral dose of OROS paliperidone in schizophrenia.
-
CLINICAL_TRIALS trial_result · 2011-06-09Clinical Trial Update: A Comparison of the Pharmacokinetics and Safety of Long-acting Injectable Risperidone When Administered to Gluteal or Deltoid Intramuscular Injection Sites in Stable Schizophrenia Patients. [Phase 3]
Phase 3 trial evaluating the pharmacokinetics and safety of long-acting injectable risperidone when administered in gluteal versus deltoid i…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2011-06-08FDA Approved: RISPERIDONE — Supplemental Application (Zydus Lifesciences Limited)
FDA records a supplemental application for risperidone by Zydus Lifesciences Limited; specifics of the label changes are not provided in the…
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia [Phase 3]
A Phase 3 trial evaluating the effectiveness and safety of risperidone in adolescents with schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia [Phase 3]
This clinical trial update reports the efficacy and safety results of risperidone in adolescents with schizophrenia in a Phase 3 study.
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia [Phase 3]
Phase 3 trial comparing a long-acting antipsychotic with placebo in schizophrenia; the study has completed and reported efficacy and safety …
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia [Phase 3]
A Phase 3 safety study of paliperidone ER in geriatric patients with schizophrenia has been completed.
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia [Phase 3]
Phase 3 long-term study evaluating the safety and efficacy of long-acting injectable risperidone in schizophrenia; the trial has completed.
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: Study of CYR-101 in Patients With Schizophrenia [Phase 2]
CYR-101, developed by Cyrenaic Pharmaceuticals, completed a Phase 2 trial in schizophrenia. This update provides the trial status of the stu…
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: Investigate Risperidone for the Treatment of Schizophrenia in Adolescents [Phase 3]
A Phase 3 trial evaluating risperidone for the treatment of schizophrenia in adolescents has completed.
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia [Phase 3]
Phase 3 trial evaluating the effectiveness and safety of three dosing regimens of paliperidone palmitate in adults with schizophrenia has co…
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305. [Phase 3]
A 52-week open-label extension study following the double-blind Phase 3 efficacy and safety trial for schizophrenia (R076477-SCH-305) has be…
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: A Study of QT and QTc Intervals in Patients Administered Immediate Release Paliperidone [Phase 1]
Phase 1 study evaluating the effects of immediate-release paliperidone on QT and QTc intervals in patients with schizophrenia or schizoaffec…
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia. [Phase 3]
A Phase 3 clinical trial evaluating the effectiveness and safety of paliperidone extended-release (Invega ER) tablets to prevent recurrence …
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: A Study of the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese Volunteers [Phase 1]
Phase 1 study in healthy Japanese volunteers to assess the effect of food on the pharmacokinetics of ER OROS Paliperidone.
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: A Study of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS Paliperidone [Phase 1]
A Phase 1 study evaluated whether trimethoprim alters the pharmacokinetics of the extended-release paliperidone formulation (Invega ER) in i…
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia [Phase 3]
A Phase 3 trial evaluating three fixed dosages of paliperidone extended-release tablets in combination with olanzapine for schizophrenia has…
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder [Phase 3]
A phase 3 randomized trial comparing a long-acting injectable risperidone formulation to olanzapine tablets in adults with schizophrenia or …
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function [Phase 1]
Phase 1 pharmacokinetic study of paliperidone in volunteers with normal or impaired liver function to assess drug exposure and safety consid…
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With Schizophrenia [Phase 3]
A Phase 3 safety and tolerability study of paliperidone palmitate injected in the shoulder or buttock for schizophrenia, with the trial comp…
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia [Phase 3]
This is a 52-week open-label extension of a 6-week double-blind, placebo- and active-controlled Phase 3 study evaluating the long-term safet…
-
CLINICAL_TRIALS trial_result · 2011-06-08Clinical Trial Update: As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations [Phase 1]
Phase 1 pharmacokinetic study comparing paliperidone Extended-Release with risperidone Immediate-Release in adults with Schizophrenia or Sch…